2024
Sleep apnea in schizophrenia: Estimating prevalence and impact on cognition
Ghazikhanian S, Surti T. Sleep apnea in schizophrenia: Estimating prevalence and impact on cognition. Journal Of Psychiatric Research 2024, 177: 330-337. PMID: 39068777, DOI: 10.1016/j.jpsychires.2024.07.028.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaPrevalence of obstructive sleep apneaCognitive deficits of schizophreniaWorking memory test scoresDeficits of schizophreniaSleep apneaImpaired cognitive domainsSpeed of processingDisabling cognitive deficitsMemory test scoresHigher cognitive capacityFunctional capacity performanceAssociated with lower speedsVerbal learningCognitive domainsCompromised cognitionSchizophreniaRisk of obstructive sleep apneaEffects of sleep apneaCognitive capacityCognitive impairmentPredicting obstructive sleep apneaSelf-reportMedical illnessFunctional capacity assessmentPsychotic Disorders and Schizophrenia
Surti T. Psychotic Disorders and Schizophrenia. 2024 DOI: 10.1016/b978-0-323-95702-1.00074-9.Peer-Reviewed Original ResearchPsychotic disordersSymptoms of schizophrenia-spectrum disordersDifferential diagnosis of schizophreniaSchizophrenia spectrum disordersDiagnosis of schizophreniaDecreased emotional expressionNon-psychiatric conditionsAssociated with increased disabilityPsychotic symptomsDisorganized speechDisorganized behaviorCognitive symptomsPsychotic diseasesEmotional expressionSchizophreniaLack of motivationDisordersSymptomsClinical presentationDifferential diagnosisClinical managementDelusionsHallucinationsRisk factorsIncreased mortality
2023
Snoozing on Pot: Cannabis and Sleep
Skosnik P, Surti T. Snoozing on Pot: Cannabis and Sleep. 2023, 333-345. DOI: 10.1017/9781108943246.032.Peer-Reviewed Original ResearchMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsHealth teamsImpact of exposureCannabis dependenceAdverse effectsCannabisSynthetic cannabinoidsIllnessPsychosisCannabinoidsNew research findingsAssociationComplex associationNeurodevelopmentPutative modelSleepSchizophreniaRandomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.Peer-Reviewed Original ResearchConceptsGlycine transporter 1Cytochrome P450 2D6 extensive metabolizersGlyT1 inhibitorsWeeks of washoutWeeks of CTMedication adherenceReceptor hypofunctionImpaired neuroplasticityPharmacodynamic variabilityNMDAR functionExtensive metabolizersTreatment periodPsychotic symptomsStable outpatientsCognitive impairmentGlyT1 occupancyTransporter 1CTNeuroplasticityCognitive training strategiesSchizophreniaComputerized CTCognitive performanceAugmentation studiesGreater improvement
2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels